<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35386353</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2452-199X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioactive materials</Title>
          <ISOAbbreviation>Bioact Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>DNA-based artificial dendritic cells for in situ cytotoxic T cell stimulation and immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>160</StartPage>
          <EndPage>172</EndPage>
          <MedlinePgn>160-172</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2021.12.001</ELocationID>
        <Abstract>
          <AbstractText>In immunotherapy, ex vivo stimulation of T cells requires significant resources and effort. Here, we report artificial dendritic cell-mimicking DNA microflowers (DM) for programming T cell stimulation in situ. To mimic dendritic cells, DNA-based artificial dendritic microflowers were constructed, surface-coated with polydopamine, and further modified with anti-CD3 and anti-CD28 antibodies to yield antibody-modified DM (DM-A). The porous structure of DM-A allowed entrapment of the T cell-stimulating cytokine, ineterleukin-2, yielding interleukin-2-loaded DM-A (DM-AI). For comparison, polystyrene microparticles coated with polydopamine and modified with anti-CD3 and anti-CD28 antibodies (PS-A) were used. Compared to PS-A, DM-AI showed significantly greater contact with T cell surfaces. DM-AI provided the highest ex vivo expansion of cytotoxic T cells. Local injection of DM-AI to tumor tissues induced the recruitment of T cells and expansion of cytotoxic T cells in tumor microenvironments. Unlike the other groups, model animals injected with DM-AI did not exhibit growth of primary tumors. Treatment of mice with DM-AI also protected against growth of a rechallenged distant tumor, and thus prevented tumor recurrence in this model. DM-AI has great potential for programmed stimulation of CD8<sup>+</sup> T cells. This concept could be broadly extended for the programming of specific T cell stimulation profiles.</AbstractText>
          <CopyrightInformation>© 2021 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Quoc-Viet</ForeName>
            <Initials>QV</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jaiwoo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Byun</LastName>
            <ForeName>Junho</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shim</LastName>
            <ForeName>Gayong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Systems Biomedical Science, Soongsil University, Seoul, 06978, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oh</LastName>
            <ForeName>Yu-Kyoung</ForeName>
            <Initials>YK</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioact Mater</MedlineTA>
        <NlmUniqueID>101685294</NlmUniqueID>
        <ISSNLinking>2452-199X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Artificial dendritic cell</Keyword>
        <Keyword MajorTopicYN="N">DNA microflower</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">In situ T cell stimulation</Keyword>
        <Keyword MajorTopicYN="N">Programmed T cell expansion</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35386353</ArticleId>
        <ArticleId IdType="pmc">PMC8940766</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioactmat.2021.12.001</ArticleId>
        <ArticleId IdType="pii">S2452-199X(21)00553-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Waldman A.D., Fritz J.M., Lenardo M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 2020;20(11):651–668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7238960</ArticleId>
            <ArticleId IdType="pubmed">32433532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Tian S., Sun J., Zhang J., Lin L., Hu C. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma. BMC Cancer. 2020;20:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7406390</ArticleId>
            <ArticleId IdType="pubmed">32758195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao W., He J.C., Yang Y., Wang J.M., Qian Y.W., Yang T., Ji L. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis. Sci. Rep. 2017;7(1):1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5548736</ArticleId>
            <ArticleId IdType="pubmed">28790445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saleh R., Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32721551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunshine J.C., Green J.J. Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine. 2013;8(7):1173–1189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3951141</ArticleId>
            <ArticleId IdType="pubmed">23837856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhodes K.R., Green J.J. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Mol. Immunol. 2018;98:13–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6084459</ArticleId>
            <ArticleId IdType="pubmed">29525074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steenblock E.R., Fadel T., Labowsky M., Pober J.S., Fahmy T.M. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J. Biol. Chem. 2011;286(40):34883–34892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3186438</ArticleId>
            <ArticleId IdType="pubmed">21849500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunshine J.C., Perica K., Schneck J.P., Green J.J. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 2014;35(1):269–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3902087</ArticleId>
            <ArticleId IdType="pubmed">24099710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Song S., Jin X., Wan X., Shahzad K.A., Pei W., Zhao C., Shen C. An artificial antigen-presenting cell delivering 11 immune molecules expands tumor antigen–specific CTLs in ex vivo and in vivo murine melanoma models. Cancer Immunol Res. 2019;7(7):1188–1201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31113806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Akiva E., Rhodes K.R., Meyer R.A., Green J.J. Fabrication of anisotropic polymeric artificial antigen presenting cells for CD8+ T cell activation. JoVE: JoVE. 2018;(140):58332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6235518</ArticleId>
            <ArticleId IdType="pubmed">30371668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Q.V., Suh J., Choi J.J., Park G.T., Lee J.W., Shim G., Oh Y.K. In situ nanoadjuvant-assembled tumor vaccine for preventing long-term recurrence. ACS Nano. 2019;13(7):7442–7462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31180642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sciullo P.D., Menay F., Cocozza F., Gravisaco M.J., Waldner C.I., Mongini C. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Clin. Immunol. 2019;203:154–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31048012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Li Q., Shim G., Oh Y.K. Melanin-loaded CpG DNA hydrogel for modulation of tumor immune microenvironment. J. Control Release. 2021;330:540–553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33373649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E., Zwi‐Dantsis L., Reznikov N., Hansel C.S., Agarwal S., Stevens M.M. One‐pot synthesis of multiple protein‐encapsulated DNA flowers and their application in intracellular protein delivery. Adv. Mater. 2017;29(26):1701086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5516917</ArticleId>
            <ArticleId IdType="pubmed">28474844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shim G., Park J., Kim M.G., Yang G., Lee Y., Oh Y.K. Noncovalent tethering of nucleic acid aptamer on DNA nanostructure for targeted photo/chemo/gene therapies. Nanomedicine. 2020;24:102053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31344502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickey J.W., Vicente F.P., Howard G.P., Mao H.-Q., Schneck J.P. Biologically inspired design of nanoparticle artificial antigen-presenting cells for immunomodulation. Nano Lett. 2017;17(11):7045–7054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6709596</ArticleId>
            <ArticleId IdType="pubmed">28994285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggermont L.J., Paulis L.E., Tel J., Figdor C.G. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4154451</ArticleId>
            <ArticleId IdType="pubmed">24998519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang W.-R., Wang Y., Cui P.-F., Xing L., Lee J., Kim D., Jiang H.-L., Oh Y.-K. Applications of π-π stacking interactions in the design of drug-delivery systems. J. Contr. Release. 2019;294:311–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30550939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Ai K., Lu L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem. Rev. 2014;114(9):5057–5115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24517847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung A.S., Zhang D.K., Koshy S.T., Mooney D.J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 2018;36(2):160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5801009</ArticleId>
            <ArticleId IdType="pubmed">29334370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Kurlander R.J. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J. Transl. Med. 2010;8:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2987859</ArticleId>
            <ArticleId IdType="pubmed">20977748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 2008;16(4):765–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18334990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zappasodi R., Nicola M., Carlo-Stella C., Mortarini R., Molla A., Vegetti C., Albani S., Anichini A., Gianni A.M. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica. 2008;93(10):1523–1534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18728033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal S., Eksteen-Akeroyd Z.H., Jacobs M.J., Hammink R., Koepf M., Lambeck A.J., van Hest J.C.M., Wilson C.J., Blank K., Figdor C.G., Rowan A.E. Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy. Chem. Sci. 2013;4(11):4168–4174.</Citation>
        </Reference>
        <Reference>
          <Citation>Sunshine J.C., Perica K., Schneck J.P., Green J.J. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 2014;35(1):269–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3902087</ArticleId>
            <ArticleId IdType="pubmed">24099710</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
